Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions

This study has been completed.
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
First received: July 26, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
Basal Cell Carcinoma (BCC) is the most common malignant growth in the world. Treatment is primarily surgical with the goal of excising the growth in its entirety. When pathology results show that this has not been achieved, a re-excision is routinely performed. This study examines retrospectively the percentage of re-excisions of BCC that actually proved to be positive (exhibited growth) among those re-excisions performed at Rambam Healthcare Campus and Zvulun Community Medical Center during the years 2008-10.

Basal Cell Carcinoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Rates of Positive BCCs in Re-excisions

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 600
Study Start Date: January 2008
Study Completion Date: February 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All patients that underwent an incomplete BCC excision during the years 2008-2010.

Inclusion Criteria:

All patients that underwent an incomplete BCC excision during the years 2008-2010.

Exclusion Criteria:

Patients that underwent an incomplete BCC excision and were subsequently referred to undergo a MOHS procedure.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Prof. Yehuda Ullmann, Head, Plastic and Reconstructive Surgery Department, Rambam Healthcare Campus
ClinicalTrials.gov Identifier: NCT01403480     History of Changes
Other Study ID Numbers: 0064-11-RMB-CTIL 
Study First Received: July 26, 2011
Last Updated: July 26, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:
Basal Cell Carcinoma

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on May 22, 2016